|
1
|
A’Hern RP, Smith IE and Ebbs SR:
Chemotherapy and survival in advanced breast cancer: the inclusion
of doxorubicin in Cooper type regimens. Br J Cancer. 67:801–805.
1993.PubMed/NCBI
|
|
2
|
Fossati R, Confalonieri C, Torri V,
Ghislandi E, Penna A, Pistotti V, Tinazzi A and Liberati A:
Cytotoxic and hormonal treatment for metastatic breast cancer: a
systematic review of published randomized trials involving 31,510
women. J Clin Oncol. 16:3439–3460. 1998.PubMed/NCBI
|
|
3
|
Paterson AH, Szafran O, Cornish F, Lees AW
and Hanson J: Effect of chemotherapy on survival in metastatic
breast cancer. Breast Cancer Res Treat. 1:357–363. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pentheroudakis G, Razis E, Athanassiadis
A, Pavlidis N and Fountzilas G: Paclitaxel-carboplatin combination
chemotherapy in advanced breast cancer: accumulating evidence for
synergy, efficacy, and safety. Med Oncol. 23:147–160. 2006.
View Article : Google Scholar
|
|
5
|
Polyzos A, Tsavaris N, Kosmas C, Gogas H,
Toufexi H, Kosmidis C, Markopoulos C, Giannopoulos A, Papadopoulos
O, Stamatiadis D and Kouraklis G: Full dose paclitaxel plus
vinorelbine as salvage chemotherapy in anthracycline-resistant
advanced breast cancer: a phase II study. J Chemother. 15:607–612.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seo JH, Oh SC, Choi CW, Kim BS, Shin SW,
Kim YH, Kim JS, Kim AR, Lee JB and Koo BH: Phase II study of a
gemcitabine and cisplatin combination regimen in taxane resistant
metastatic breast cancer. Cancer Chemother Pharmacol. 59:269–274.
2007.PubMed/NCBI
|
|
7
|
Holmes FA, Walters RS, Theriault RL,
Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi
GN: Phase II trial of taxol, an active drug in the treatment of
metastatic breast cancer. J Natl Cancer Inst. 83:1797–1805. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seidman AD, Reichman BS, Crown JP, Yao TJ,
Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P,
et al: Paclitaxel as second and subsequent therapy for metastatic
breast cancer: activity independent of prior anthracycline
response. J Clin Oncol. 13:1152–1159. 1995.PubMed/NCBI
|
|
9
|
Ito Y, Horikoshi N, Watanabe T, Sasaki Y,
Tominaga T, Okawa T, Tabei T, Kuraishi Y, Tamura K, Abe R, Kitajima
M, Yamaguchi S, Kobayashi T, Koyama H, Orita K, Takashima S, Nomura
Y and Ogawa M: Phase II study of paclitaxel (BMS-181339)
intravenously infused over 3 hours for advanced or metastatic
breast cancer in Japan. BMS-181339 Breast Cancer Study Group.
Invest New Drugs. 16:183–190. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seidman AD, Hudis CA, Albanell J, Tong W,
Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J
and Norton L: Dose-dense therapy with weekly 1-hour paclitaxel
infusions in the treatment of metastatic breast cancer. J Clin
Oncol. 16:3353–3361. 1998.PubMed/NCBI
|
|
11
|
Lokich JJ, Ahlgren JD, Gullo JJ, Philips
JA and Fryer JG: A prospective randomized comparison of continuous
infusion fluorouracil with a conventional bolus schedule in
metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program
Study. J Clin Oncol. 7:425–432. 1989.
|
|
12
|
Ota K, Taguchi T and Kimura K: Report on
nationwide pooled data and cohort investigation in UFT phase II
study. Cancer Chemother Pharmacol. 22:333–338. 1988.PubMed/NCBI
|
|
13
|
Tashiro H, Nomura Y and Ohsaki A: A double
blind comparative study of tegafur (FT) and UFT (a combination of
tegafur and uracil) in advanced breast cancer. Jpn J Clin Oncol.
24:212–217. 1994.PubMed/NCBI
|
|
14
|
Passardi A, Maltoni R, Milandri C,
Cecconetto L, Massa I, Zoli W, Tesei A, Fabbri F, Nanni O and
Amadori D: Phase I study of paclitaxel and uracil plus tegafur
combination in patients with pretreated metastatic breast cancer:
drug sequencing based on preclinical modelling studies. Oncology.
72:118–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim R, Osaki A and Toge T: Feasibility and
therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for
relapsed breast cancer. Oncol Rep. 10:145–150. 2003.PubMed/NCBI
|
|
16
|
Kimura M, Koida T and Yanagita Y: Weekly
administration of paclitaxel for advanced or metastatic breast
cancer-short-course premedications for outpatients. Gan To Kagaku
Ryoho. 27:1703–1708. 2000.PubMed/NCBI
|
